BRIEF—Extended access program for PharmaMar's lurbinectedin in USA

PharmaMar and the contract research organization, Bionical Emas, have announced the launch of an expanded access program for the Spanish drugmaker’s cancer drug, lurbinectedin.

This will create access for US patients who have relapsed small cell lung cancer, where they are unable to enter clinical trials and do not have appropriate alternative treatments.

Lurbinectedin is an unapproved therapy but last month PharmaMar announced the filing of its New Drug Application for the treatment of relapsed SCLC with the US Food and Drug Administration under the accelerated approval program.